Stock Evaluator: Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Inc. IXHL

$2.94 0.01 0.34%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 71,283
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Commentary & Analysis


Financial Summary

Share Statistics IXHL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $35.1 $569.9 13%
Shares Out (Mil) 12.3 44.8 24%
Institutional Ownership 37.7% 84.6% 16%
Float (Mil) 9.9 45.1 19%
Beta 2.84 0.67 97%
Avg Daily Volume (000s) 94 294 35%
Price Change
(52-week)
(90.9%) 65.2% 4%
Growth IXHL Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) (71.1%) (2.0%) 4%
EPS (5yr) (135.1%) 14.9% 0
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 66.7% (14.9%) 96%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials IXHL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $230 na
Net Income (TTM) (Mil) ($48) ($11) 16%
EPS (TTM) ($5.216) ($0.600) 8%
Operating Cash Flow (TTM) (Mil) ($18) ($6) 15%
Net Cash Flow (TTM) (Mil) $68 $4 74%
Long-Term Debt (Q1) (Mil) $0 $7 0%
Enterprise Value (Q1) (Mil) ($36) $493 1%
Valuation IXHL Industry
Median
Percentile
(All Stocks)
P/B 0.53 2.89 9%
P/E na 20.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios IXHL Industry
Median
Percentile
(All Stocks)
Gross Margin na 65.9% na
Net Margin na (0.2%) na
ROA (100.4%) (25.5%) 5%
ROE (117.2%) (21.4%) 8%
Liabilities to Assets 6.3% 35.5% 3%
F-Score 4 3 34%

Incannex Healthcare Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors